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leading cause by 2030 in Western countries 1, 2 ; therefore, the development of a new multidisciplinary treatment strategy is an urgent requirement. The possibility of improving treatment outcomes through the performance of multidisciplinary neoadjuvant chemotherapy or chemoradiotherapy, which results in the reduction of tumor size and rate of lymph node metastasis accompanied by an increase in the R0 resection rate, has been reported. 3 Therefore, identifying novel biomarkers for the prediction of treatment outcomes is essential to further improve patient prognoses.
Thus far, several biomarkers have been reported following preoperative treatment focusing on serum protein levels, 4 specific gene mutations 5 based on next-generation sequencing, and pathological improvement 6 in the resected specimens based on criteria such as the Evans and College of American Pathologists classifications.
In addition to serological, biological and histopathological assessments for the identification of biomarkers, immunological assessment has been recently accepted because of its ability to reflect host immune response to the tumor based on the cancer immunity cycle 7 in the tumor microenvironment (TME), which comprises various components, such as tumor cells as well as blood vessels, fibroblasts, host immune cells and extracellular matrix. their roles in the immune system are similar to those of SLO, characterized by recognition of antigens and production of antigen-specific antibodies. 9 Initially, TLO were identified in studies focusing on chronic inflammatory diseases, such as rheumatoid arthritis, Crohn's diseases and Helicobacter pylori infection. 10 However, it was recently found that TLO are also present in malignant tissues, [11] [12] [13] and their clinical relevance has been reported in pancreatic cancer. Previous studies found that patients with high expression of intratumoral TLO in cancer tissues had favorable prognoses in terms of overall survival (OS) and disease-free survival (DFS), among patients who had undergone curative resection without preoperative treatment.
14
In the present study, we investigated the clinical relevance of TLO by observing the differences between patients who received NAC and those who underwent curative surgical resection (surgery first [SF] ).
This study aimed to investigate TLO expression, functional differences in immunological aspects and differences in prognoses between patients belonging to the 2 groups in the TME, and to identify novel biomarkers for the reflection of prognoses following chemoradiotherapy.
| MATERIAL S AND ME THODS

| Patients and samples
The present study included 146 patients diagnosed be- 
| Evaluation of tertiary lymphoid organs
The resected specimens of all 140 patients were formalin-fixed.
In the present study, we selected tissue slides with the maximum divided surface, which were stained with H&E, and then detected the tumor area and identified TLO by microscopic observation.
The microscopic images were imported as digital photo files using a NanoZoomer Digital Pathology system (Hamamatsu Photonics, Hamamatsu, Japan). We measured the area of the TLO (mm 2 ), and the total area of the PDAC tissue (mm 2 ) using Image J software (NIH, Bethesda, MD, USA). Then, we calculated the TLO area/total PDAC tissue area ratio (TLO/tumor ratio) to compensate for the bias affecting TLO due to the tumor size of the SF group and the NAC group.
| Immunohistochemistry
Tissue sections were deparaffinized in xylene and rehydrated through a graded ethanol series. Heat-induced antigen retrieval was carried out in a high or low-pH antigen retrieval buffer (DakoCytomation, Glostrup, Denmark were applied for 30 minutes. These sections were visualized using the HRP-labeled polymer method (EnVision FLEX System, Dako).
Immunostained sections were counterstained with hematoxylin, dehydrated in ethanol, and cleared in xylene. These data are summarized in Table S1 .
| Evaluation criteria of the immune cells in the tertiary lymphoid organs
The lymphocytes or immune cells stained diffusely or partly with antibodies, such as CD4, CD8, CD20, CD80 and CD163, in the TLO were measured to determine the area ( 
| Statistical analysis
Differences between the 2 groups were analyzed using MannWhitney U-tests. Categorical variables were compared using Fisher's exact test or a χ 2 -test. The association between 2 continuous variables was calculated using Spearman's rank correlation analysis.
OS was defined as the time from surgery to death from any cause in the SF group and the time from the start of NAC to death from any cause in the NAC group. The proportion of OS was calculated using the Kaplan-Meier method. Comparisons between the 2 groups were performed using a log-rank test. Univariate and multivariate analyses were performed using the Cox proportional hazards model.
All differences with a P-value of <0.05 were considered significant.
Statistical analyses were performed using JMP 13 (SAS Institute Inc., Cary, NC, USA).
| RE SULTS
| Clinicopathological features of the patients
The demographic background characteristics of all patients in this study are listed in Table 1 . There were no significant differences in the background characteristics between the SF and NAC groups in terms of age, sex, tumor localization, lymph node and distant metastasis, pathological staging, histological differentiation, and presence or absence of adjuvant therapy. Data on the preoperative treatment regimens in the NAC group are summarized in Table S2 . Sixteen and four patients received S-1 or gemcitabine alone, respectively; 8 patients received both S-1 and gemcitabine, and 2 patients received FOLFIRINOX, which comprised 5-fluorouracil (5-FU), oxaliplatin There were no significant differences in terms of the background characteristics between the surgery first and the neoadjuvant chemoradiotherapy group. Pbt, pancreas body and tail; Ph, pancreas head. 
| Comparisons of the total tumor area, tertiary lymphoid organ area, and tertiary lymphoid organ/tumor ratio between the surgery first and neoadjuvant chemoradiotherapy groups
We measured the total area of the tumor (mm The TLO expression rate was 91.4% (128/140) and there was no significant difference between the SF (88/93 94.6%) group and the NAC (40/47 85.1%) group (P = 0.0575). In patients with TLO expression, the total area of the tumor and the area of the TLO were significantly smaller in the NAC group than those in the SF group (Table   S3 ). There was a weak correlation between the total tumor area and the TLO area (r = 0.36, P < 0.001) ( Figure S1 ). Differences in the total tumor area between the SF and NAC groups were thought to be associated with the shrinkage effect of NAC. Differences in the TLO area between the SF and NAC groups were thought to be a result of modification bias influenced by tumor reduction due to anticancer drugs. Based on these data, the TLO/tumor ratio was considered appropriate as a parameter to compensate for TLO by tumor size.
| Immunohistochemical analysis
To analyze the components inside the TLO from an immunological viewpoint, we investigated the functional differences between the SF group and the NAC group in the TME by immunostaining Table 2 ).
Furthermore, we performed a subgroup analysis dividing each group of patients into "high" and "low" groups with a median TLO/ tumor ratio value (as shown in Figure S2 ). For the NAC group, the proportion of CD20+ B cells was significantly higher among those with a high TLO/tumor ratio than in those with a low TLO/tumor ratio (42.7% vs 23.2%, P = 0.0133). Moreover, the proportion of PNAd+ HEV was significantly higher in the high TLO/tumor ratio group (3.5% vs 1.8%, P = 0.0009). In contrast, the proportions of Foxp3+ Treg cells and PD-1 positive lymphocytes, both acting immunosuppressively, were significantly higher in the low TLO/tumor ratio group than in the high TLO/tumor ratio group (2.9% vs 6.1%, P = 0.0208; 1.5% vs 5.1%, P = 0.0086). There was no significant vs 0.56%, P = 0.4040, 3.7% vs 3.7%, P = 0.6715). The proportion of Ki-67+ lymphocytes tended to be higher in the low TLO/tumor ratio group, but the difference was not significant (3.1% vs 6.8%, P = 0.0609) (Table S4A ). In the SF group, there was no significant difference between the high TLO/tumor ratio group and the low TLO/ (Table   S4B ).
| Prognostic analysis
In terms of OS, the NAC group had a significantly better prognosis than the SF group (P = 0.0017) ( Figure 3A) . The median follow-up time was 749.5 days, and the 2-year and 5-year survival rates of the SF group were 51.9% and 17.7%, while those of the NAC group were 82.0% and 44.2%, respectively. Regarding for the postoperative adjuvant therapy, there was no significant difference in overall survival with and without adjuvant therapy, therefore it suggested that adjuvant therapy had no impact on patients' overall survival in both SF and NAC group (data not shown). In the subgroup analysis, Kaplan-Meier curving plots showed that patients in the NAC group with high TLO/tumor ratios had better prognoses than those with low TLO/tumor ratios (P = 0.0328); there were no corresponding significant differences in the SF group (P = 0.6719) ( Figure 3B,C) . The demographic background characteristics of the patients in each group are listed in Table S5A (NAC) and 0.003-0.163, P < 0.0001) and a high TLO/tumor ratio (HR: 0.056, 95% CI: 0.006-0.297, P < 0.0001) were determined as independent favorable prognostic factors (Table 3) .
| D ISCUSS I ON
In this study, we investigated the clinical relevance of TLO in PDAC following chemoradiotherapy. TLO were originally defined as lymphoid organs characterized by the expression of lymphocyte F I G U R E 3 Overall survival of the 140 patients with pancreatic cancer according to the performance of neoadjuvant chemoradiotherapy or upfront surgical resection (A), and differences in the overall survival between the SF group and the NAC group according to the patients' TLO/tumor ratio. B, In the NAC group. C, In the SF group. The OS curves were estimated using the Kaplan-Meier method, and differences between the 2 groups were evaluated using a log-rank test. The number of patients at risk is shown under the OS curves. HEV, high endothelial venule; NAC, neoadjuvant chemoradiotherapy; OS, overall survival; SF, surgery first; TLO, tertiary lymphoid organ aggregates without a capsule. TLO formation is associated with the generation of encapsulated SLO. 16 However, TLO formation is distinct from the preprogrammed ontogenic processes that are associated with secondary lymphoid organogenesis and it does not occur in all patients. 16 During chronic inflammatory reactions, lymphocytes can accumulate and lead to the de novo formation of B cell follicles and T cell areas. 9, 10 This phenomenon has been termed "tertiary lymphoid neogenesis" or "TLO formation." 10, 16 Despite the presence of structural differences between SLOs and TLO, various mechanisms that control the initial development, cellular composition and functional maintenance of these structures are shared. [9] [10] [11] [12] [13] 16 In cancer, the presence of tumor-associated TLO correlates with patients' prognoses depending on the tumor types and the cell composition inside the TLO, and it is suggested that they coordinate the endogenous antitumor immune responses that can improve patient survival positively. 17 in PDAC tissues appeared to be an independent prognostic factor; moreover, it represented a TME that was less vulnerable to can- Here, we demonstrated for the first time the development of TLO following chemoradiotherapy based on novel data associated with the functional mechanisms behind the immunological compartments inside the TLO and how TLO affect patients' prognoses. In our data, the proportions of CD8+ T lymphocytes and PNAd+ HEV composed of TLO were higher in the NAC group than in the SF group.
In contrast, the proportion of PD-1+ lymphocytes inside the TLO was lower in the NAC group. Moreover, the proportions of Ki-67+ lymphocytes and CD163+ M2 macrophages were higher in the NAC group than in the SF group. These data suggest that lymphocytes and antigen-presenting cells (APC) were actively induced into the TME by an increase in the HEV levels, which caused the activation In the multivariate analysis, the absence of lymph node metastasis and a high TLO/tumor ratio were considered as independent favorable prognostic factors. CI, confidential interval; HR, hazard ratio; NAC, neoadjuvant chemoradiotherapy; OS, overall survival; Pbt, pancreas body and tail; Ph, pancreas head; TLO, tertiary lymphoid organ. a Cox-regression proportional hazards model. Similar to the findings of a previous study, our data also showed the efficacy of PNAd+ HEV, the proportion of which was higher in the NAC group than in the SF group, resulting in favorable prognoses. In the subgroup analysis using the TLO/tumor ratio, patients with a high TLO/tumor ratio showed a higher proportion of HEV within the TLO and significantly better prognoses than those with a low TLO/tumor ratio (as shown in Table S4A , Figure 3B ). This result suggested that the abundance of lymphocytes, which were induced to infiltrate into the TME by HEV, could play a role in cellular or humoral immunity.
In the process of investigating effector mechanisms, we also Previous studies demonstrated that administration of chemoradiotherapy preoperatively can prove useful in reducing Treg cell levels 36 or induce the accumulation of CD4+ and CD8+ cells in the TME; a high accumulation of CD8+ cells might be a good prognostic marker in pancreatic cancer. 37 Although the association between TIL and TLO, one of the limitations of this study, should be investigated in future analysis, our data are in agreement with those of previous studies suggesting that TLO may be activated by the tumor-associated antigen released by tumor destruction following chemoradiotherapy, accompanied by B cell infiltration, promotion of the proliferation of immune cells, development of antigen presentation, and recognition and suppression of PD-1+ cells, and leading to the angiogenesis of HEV.
In conclusion, we showed the influence of preoperative chemoradiotherapy on the immunological elements in the TME, which resulted in favorable prognoses in PDAC patients.
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